TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01212471
Drug: Bromfenac Ophthalmic Solution A
Normalized name: bromfenac Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT01212471
Drug: Bromfenac Ophthalmic Solution B
Normalized name: bromfenac Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT01212471
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT03318315
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT00343200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
Study: NCT00510809
Drug: Policosanol
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 20 mg daily
Study: NCT00510809
Drug: Policosanol Plus Already In Use Statin Therapy
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 20 mg daily Statin Therapy
Study: NCT02167945
Drug: ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use
Study: NCT02167945
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use
Study: NCT00375427
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Study: NCT01106157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
Study: NCT01106157
Drug: Pegylated GCSF
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
Study: NCT01000506
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline every four weeks by i.v.
Study: NCT01053533
Drug: Chinese herbal medicines plus western therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary
Study: NCT01053533
Drug: western therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: supportive therapy and antivirus therapy when necessary
Study: NCT00209144
Drug: Intensive insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04564456
Drug: ADVAIR DISKUS® 500/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations Reference product in one study period
Study: NCT00924001
Drug: DMF5 Melanoma Reactive TIL
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
Study: NCT00924001
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day x 2 days intravenously
Study: NCT04858841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer placebo powder once a day in eligible patients
Study: NCT01352208
Drug: ASP9521
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03698474
Drug: Natrium picosulfate / Magnesium citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: bowel preparation formula
Study: NCT03698474
Drug: Polyethylene glycol / Ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: bowel preparation formula
Study: NCT03698474
Drug: Natrium/ Kalium/ Magnesium sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: bowel preparation formula
Study: NCT02994927
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally or intravenously administered
Study: NCT02994485
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
Study: NCT01735383
Drug: Etodolac Tablets USP 500mg
Normalized name: etodolac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet once a day
Study: NCT00441844
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00159640
Drug: PD-217,014
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01735383
Drug: Etodolac Tablets USP 500 mg
Normalized name: etodolac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet once a day
Study: NCT03183752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg placebo three times daily
Study: NCT01194219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical matching placebo
Study: NCT01194219
Drug: Topical treatments or phototherapy
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
Study: NCT00048607
Drug: Comparator: Placebo (Unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00781443
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating subcutaneous injection
Study: NCT03125980
Drug: capecitabine plus oxaliplatin after surgery
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W
Study: NCT02630069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500mg once a day for 12 weeks
Study: NCT04598269
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical solution containing no ATI-1777
Study: NCT01927055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match droxidopa capsules and strength designations
Study: NCT04365933
Drug: EYP001a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01154621
Drug: AZD9742
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
Study: NCT01154621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 5% dextrose solution
Study: NCT01888796
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03608514
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
Study: NCT03375021
Drug: CX717 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX717 200 mg capsules BID
Study: NCT03375021
Drug: CX717 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX717 4 X 200 mg capsules BID
Study: NCT03375021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 200 mg or 800 mg capsules BID
Study: NCT02935608
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT01564823
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine: 2.5 mg/kg of weight/day. 3 months.
Study: NCT02840279
Drug: BPN14770
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
Study: NCT02840279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01484652
Drug: COV795
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets taken every 12 hours
Study: NCT01484652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets taken every 12 hours
Study: NCT02935608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT02337907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: for blinding purposes
Study: NCT02337907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02838056
Drug: epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
Study: NCT01152788
Drug: rIL-21
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
Study: NCT00783601
Drug: Comparator: MK0524 + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
Study: NCT00783601
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
Study: NCT02184065
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04301323
Drug: BHVI1 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including 35 children enrolled to receive BHVI1 eye-drops once nightly
Study: NCT04301323
Drug: BHVI2 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including 35 children enrolled to receive BHVI2 eye-drops once nightly
Study: NCT00791518
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention
Study: NCT04301323
Drug: BHVI3 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
Study: NCT00171223
Drug: STI571
Approvals — FDA: no, EMA: no, PMDA: no
Description: STI571 oral capsules or tablets.
Study: NCT00149123
Drug: hydrocortisone 200 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02994927
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally administered
Study: NCT03171987
Drug: Flurbiprofen patch local application
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Attach the patch to back pain area 1 piece per day with no more than 6 hours.
Study: NCT00071760
Drug: GW433908
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir suspension bid
Study: NCT01096810
Drug: TBL 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
Study: NCT02914652
Drug: Norflouran (Placebo Evohaler(R) )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
Study: NCT04434365
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins once daily for 12±1 weeks.
Study: NCT01075698
Drug: Non-ARB (standard therapy)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering therapy except ARB
Study: NCT01075698
Drug: ARB (Telmisartan)
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 20-80 mg/day
Study: NCT00174655
Drug: Doxorubicine + docetaxel sequential
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
Study: NCT00174655
Drug: doxorubicine + cyclophosphamide sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
Study: NCT00174655
Drug: doxorubicine + cyclophosphamide combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
Study: NCT00174655
Drug: doxorubicine + docetaxel combined
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
Study: NCT04407312
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, tablet, 200mg, once daily, 30 days.
Study: NCT01265849
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
Study: NCT01265849
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
Study: NCT00185302
Drug: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
Study: NCT00185302
Drug: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
Study: NCT01309789
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV every 3 weeks (Cycles 3-8)
Study: NCT01309789
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV every 3 weeks (Cycles 1-6)
Study: NCT01309789
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 IV every 3 weeks (Cycles 3-8)
Study: NCT01309789
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 IV every 3 weeks (Cycles 1-6)
Study: NCT00853892
Drug: OxyContin® 40 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxyContin® 40 mg tablet, single dose fasting
Study: NCT01476410
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03467256
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT04003844
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coadministration
Study: NCT00506454
Drug: Lipidose
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
Study: NCT00506454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
Study: NCT01930604
Drug: NeuroBloc/Myobloc (rimabotulinumtoxinB)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04475107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01001611
Drug: CKD-501 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
Study: NCT01001611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
Study: NCT00335972
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
Study: NCT03884348
Drug: proton pump inhibitor, amoxicillin, clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
Study: NCT02110342
Drug: [14C] PF-04449913
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913
Study: NCT01741181
Drug: Placebo Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
Study: NCT01741493
Drug: ABT-494
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of ABT-494 capsules
Study: NCT01741493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo capsules
Study: NCT04288856
Drug: BIIB078
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02469454
Drug: conventional insertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
Study: NCT03984591
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone according to guidelines
Study: NCT03984591
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone according to guidelines
Study: NCT02484963
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02802592
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
Study: NCT01547000
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered up to 8 weeks.
Study: NCT00276406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Study: NCT02220933
Drug: MD1003 100mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02220933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00867451
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks
Study: NCT03909412
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
Study: NCT02882854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
Study: NCT02649920
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01127633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
Study: NCT01248442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00374881
Drug: Sorbitol+Phenylephrine
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol+Phenylephrine
Study: NCT00374881
Drug: Sorbitol+Phenylephrine+Morphine
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol+Phenylephrine+Morphine
Study: NCT00374881
Drug: Sorbitol low concentration+Phenylephrine+Morphine
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol low concentration+Phenylephrine+Morphine
Study: NCT00688467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2